SNY: 赛诺菲集团

SNY新闻

• 13:45 Regeneron: Is The Market Undervaluing Its Growth Potential (NASDAQ:REGN)
• 19:26 Sanofi: Why The Market Seems To Be Overpricing Pipeline Risk (NASDAQ:SNY)
• 13:25 GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth
• 12:38 Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push
• 12:38 诺瓦瓦克斯第二大股东抛售3260万美元股票，结束激进施压
• 05:19 Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here’s What You Should Know
• 20:09 Recursion: REC-4881 End 2026 Program Update And Collaboration Candidates In Play (RXRX)
• 17:43 赛诺菲必须在欧盟反垄断协议下澄清关于竞争对手流感疫苗的事实
• 17:43 Sanofi Must Set Record Straight on Rival Flu Shot Under EU Antitrust Deal
• 16:05 Sanofi Inks Letter Of Intent With pan-Canadian Pharmaceutical Alliance For Dupixent For Four Additional Indications
• 15:31 Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?
• 12:56 What to Expect From Regeneron Pharmaceuticals' Next Quarterly Earnings Report
• 12:42 Recursion Announces Sanofi Option Of First Immunology Drug Candidate, Triggering $10M Milestone Payment And Potential Phase 1 Trials In 2027
• 12:42 Recursion宣布赛诺菲拥有首个免疫学药物候选物的选择权，触发1000万美元里程碑付款，并可能于2027年启动I期临床试验
• 15:09 Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?
• 12:00 Why A Biotech M&A Wave May Hit This Winter
• 15:07 TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia
• 12:35 5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% Plus (October 2026)
• 20:55 Teva: 'Hold' On FDA Approval Of Weltruza And Pivot To Growth Strategy (TEVA)
• 11:58 再生元制药与赛诺菲修订许可及合作协议，共同开发并商业化四种再生元发明的新抗体；再生元预计将确认约2,200万美元的税前收购中在研研发费用
• 11:58 Regeneron Pharmaceuticals, Sanofi Amend License, Collaboration Agreement To Jointly Develop, Commercialize Four New Regeneron-Invented Antibodies; Regeneron Anticipates Pre-Tax Acquired In-Process Research And Development Charge Of ~$22M
• 18:21 An $8 Billion Reason Why Regeneron Stock Is in Focus
• 12:45 Sanofi, Regeneron Expand Immunology Alliance With New Antibodies
• 15:07 Sanofi Deepens 20-Year Drug Development Pact With Regeneron, Pledges Up to $8 Billion